BeyondSpring Inc. (NASDAQ: BYSI), a US-based biotech company, has announced the presentation of the latest results from the Phase II KeyPelms-004 study at the 39th Society for Immunotherapy of Cancer’s (SITC) Annual Meeting. The study evaluated the efficacy and safety of plinabulin combined with pembrolizumab plus docetaxel in patients with non-small cell lung cancer (NSCLC) who experienced disease progression on PD-1/PD-L1 inhibitors with and without chemotherapy.
Study Design and Results
The investigator-initiated, single-arm, open-label Phase II study demonstrated promising outcomes. In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple immunotherapy (IO) combo regimen achieved a disease control rate (DCR) of 89.3% and a median progression-free survival (PFS) of 8.6 months at a median follow-up time of 11.5 months.
Safety Profile
Moreover, the combination therapy was generally well tolerated, with 46.7% of patients experiencing grade 3 or higher treatment-related adverse effects. These results highlight the potential of plinabulin as a key component in combination therapies for NSCLC, particularly in patients who have progressed after treatment with PD-1/PD-L1 inhibitors.-Fineline Info & Tech
Leave a Reply